NEW HAVEN, Conn., May 15, 2024 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), today announced the appointment of Christopher S.

康涅狄格州纽黑文，2024年5月15日（环球通讯社）--Osmol Therapeutics是一家私营临床阶段生物制药公司，专注于开发化疗引起的周围神经病变（CIPN）和化疗引起的认知障碍（CICI）的预防性治疗，今天宣布任命Christopher S。

Eklund, Managing Director and Partner at venture capital investment firm, J.W. Childs Associates, to its Board of Directors..

风险投资公司J.W.Childs Associates董事总经理兼合伙人Eklund向董事会致辞。。

“We are pleased to welcome Chris to the Osmol Board,” said Bob Linke, MBA, President and CEO of Osmol Therapeutics. “He brings extensive experience in biopharma finance, including investments, corporate strategy and mergers and acquisitions, and we look forward to his guidance as Osmol progresses toward its vision of a future in which cancer patients won’t have to choose between their quality of life and the quality of their cancer treatment.”.

“我们很高兴欢迎克里斯加入Osmol董事会，”Osmol Therapeutics总裁兼首席执行官、MBA鲍勃·林克（BobLinke）表示。“他在生物制药财务方面拥有丰富的经验，包括投资、公司战略和并购，随着Osmol朝着癌症患者不必在生活质量和癌症治疗质量之间做出选择的未来愿景迈进，我们期待着他的指导。”。

“I am honored to join the Osmol Board and look forward to working with the leadership team as they advance OSM-0205 for the preventative treatment of CIPN and CICI. These conditions, which have no approved treatment options, impact hundreds of thousands of chemotherapy patients each year who risk sub-optimal cancer treatment in an effort to lessen the painful and debilitating effects of CIPN and CICI,” said Mr.

“我很荣幸加入Osmol董事会，并期待着与领导团队合作，推动OSM-0205对CIPN和CICI的预防性治疗。这些情况没有得到批准的治疗选择，每年影响数十万化疗患者，他们面临次优癌症治疗的风险，以减轻CIPN和CICI的痛苦和衰弱影响，”Mr。

Eklund..

埃克伦德。

Mr. Eklund is Managing Director and Partner at J.W. Childs Associates, a venture capital investment firm focused on biotechnology, pharmaceuticals, healthcare consumer products and selected other areas of interest. Prior to joining J.W. Childs Associates, he was Managing Director and Head of Corporate Strategy at New York Life Investment Management.

埃克隆德先生是J.W.Childs Associates的董事总经理兼合伙人，J.W.Childs Associates是一家风险投资公司，专注于生物技术、制药、医疗保健消费品和其他感兴趣的领域。在加入J.W.Childs Associates之前，他是纽约人寿投资管理公司的常务董事兼公司战略主管。

He has been a Chairman, Director or Managing Director at OMAX Health, Berkshire Capital Corporation, Furman Selz LLC, and Merrill Lynch & Co. Mr. Eklund received an A.B. from Harvard College and an M.B.A. from Harvard Business School. He holds the Chartered Financial Analyst designation and is a member of the New York Society of Securities Analysts. .

他曾担任OMAX Health、Berkshire Capital Corporation、Furman Selz LLC和Merrill Lynch＆Co.的董事长、董事或常务董事。Eklund先生获得了哈佛学院的学士学位和哈佛商学院的工商管理硕士学位。他拥有特许金融分析师称号，是纽约证券分析师协会会员。。

About OSM-0205

关于OSM-0205

Osmol’s lead therapeutic candidate, OSM-0205, is based on the research of Barbara Ehrlich, PhD, in neuronal calcium sensor-1 (NCS1) at Yale School of Medicine, which is designed to prevent the off-target calcium surge caused by taxanes and potentially other chemotherapy treatments associated with peripheral nerve damage.

Osmol的主要候选治疗药物OSM-0205是基于耶鲁大学医学院BarbaraEhrlich博士对神经元钙传感器-1（NCS1）的研究，该研究旨在防止紫杉烷和其他可能与周围神经损伤相关的化疗引起的脱靶钙激增。

Data from non-clinical studies conducted by Osmol show that pre-treatment with OSM-0205 prevents the pathologic damage caused by these chemotherapy agents..

Osmol进行的非临床研究数据显示，OSM-0205预处理可预防这些化疗药物引起的病理损伤。。

About Osmol Therapeutics

关于Osmol Therapeutics

Osmol Therapeutics is a privately held, clinical stage biopharma company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy and chemotherapy-induced cognitive impairment based on the ground-breaking work of Barbara Ehrlich, PhD, Professor of Pharmacology, Yale School of Medicine, and Chief Scientific Advisor, Osmol Therapeutics.

Osmol Therapeutics是一家私营的临床阶段生物制药公司，专注于开发一种治疗方法，以预防化疗引起的周围神经病变和化疗引起的认知障碍，这是基于耶鲁大学医学院药理学教授Barbara Ehrlich博士和Osmol Therapeutics首席科学顾问的开创性工作。

The company’s lead indication will be for the prevention of CIPN related to taxane treatment. As an example of the extent of this condition, up to 80% of taxane-treated patients with breast cancer have been reported to experience CIPN. Up to 50% of these patients have their taxane dose modified potentially impacting their cancer treatment.

该公司的主要适应症将用于预防与紫杉烷治疗有关的CIPN。作为这种情况程度的一个例子，据报道，多达80%的紫杉烷治疗的乳腺癌患者经历了CIPN。这些患者中多达50%的紫杉烷剂量被修改，可能会影响他们的癌症治疗。

For more information, please visit https://osmoltherapeutics.com/..

有关更多信息，请访问https://osmoltherapeutics.com/..

Contact:

联系人：

Gina Nugent

Gina Nugent

gina@nugentcommunications.com

gina@nugentcommunications.com